UNSPSC 51143406: Caffeine/ergotamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

UNSPSC 51143406 Caffeine/ergotamine is a Commodity code that classifies pharmaceutical active ingredients and finished products procured by state and local health authorities, often through cooperative purchasing arrangements. The recent opportunities tagged under this code, however, show substantial scope mismatch: Seminole County, Florida is acquiring naloxone and drug deactivation systems (opioid overdose reversal and controlled-substance destruction); Texas HHS Commission is gathering market intelligence on direct-to-manufacturer pharmacy benefit programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is soliciting generic multi-source pharmaceuticals and over-the-counter products through authorized pharmaceutical wholesalers. None of these solicitations target caffeine or ergotamine specifically, and the code assignment appears to be a tagging error in the underlying procurement notice systems rather than a genuine reflection of commodity activity.

Activity under this code is geographically dispersed across Florida, Texas, and Minnesota, with MMCAP serving a multi-state footprint including Oregon. Issuing bodies include county health departments (Seminole County), state health and human services commissions (Texas HHS), and cooperative purchasing alliances administered by state procurement offices (Minnesota). The representative recent opportunities show different procurement mechanisms: Seminole County issued an IFB (Invitation for Bid) with a July 26, 2023 deadline for naloxone and deactivation systems with quarterly delivery requirements; Texas HHS posted an RFI on April 3, 2026 as exploratory market research with no award commitment; and MMCAP released an RFP due March 26, 2026 for generic pharmaceuticals and OTC products, requiring vendor participation through three authorized wholesalers with cGMP certification and DSCSA compliance. The MMCAP solicitation emphasizes price competitiveness (75 percent weight), EDI capability, and a 3 percent administrative fee structure. Given the mismatch between the code nominal scope and recent opportunities, pursue this code only if your firm manufactures or distributes naloxone, pharmaceutical wholesaler services, or multi-source generics through cooperative purchasing channels rather than caffeine or ergotamine products.